A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease

Currently available therapies for the treatment of Alzheimer’s disease (AD) consist of cholinesterase inhibitors (ChEIs), such as donepezil, and the N-methyl-D-aspartate receptor antagonist memantine. In December 2014, the US Food and Drug Administration approved Namzaric™, a once-daily, fixed-dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Deardorff, William James, Grossberg, George T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055113/
https://www.ncbi.nlm.nih.gov/pubmed/27757016
http://dx.doi.org/10.2147/DDDT.S86463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055113/
https://www.ncbi.nlm.nih.gov/pubmed/27757016
http://dx.doi.org/10.2147/DDDT.S86463

Ejemplares similares